NEW YORK (GenomeWeb) – Sophia Genetics announced today that its Hereditary Cancer Solution has received CE-IVD certification.
The genetic screen uses Integrated DNA Technologies' xGen Lockdown Probes to look at 27 genes relevant to breast, ovarian, and gastrointestinal hereditary cancers and includes specialized analytics developed by Sophia. The CE Mark applies to the combination of target capture technology and analytics, the firm said.
In February of last year, Sophia and IDT entered into a partnership to bundle the technologies into clinical, medium-sized, next-generation sequencing panels.
"The CE-IVD marking of our Hereditary Cancer Solution illustrates our continued efforts to ensure the best accuracy in genomic testing, and is another milestone on our journey towards the democratization of data-driven medicine," Sophia Genetics CEO Jurgi Camblong said in a statement.